3WN-94585-90552
4 vaccinations
7 coded responses
22 check-ins
3 free-text entries
1 call case
- Sex
- Female
- Age at first dose
- 31-35
- ZIP prefix
- 730 / OK
- Registered
- 2020-12-22
- Relationship
- Self
- Race
- White
- Ethnicity
- Not Hispanic or Latino
Timeline
-
2020-12-22
Registered in v-safe
-
2020-12-22
Dose 1 — Pfizer-BioNTech
- 2020-12-22
- 2020-12-25
- 2020-12-26
- 2020-12-27
- 2020-12-28
-
2020-12-29
Survey response — day 7, dose 1MedDRA: Axillary pain — Feeling: GoodFree text: Pain under my left armpit but no palpable lymph nodeMedDRA releases: 2021-09,2023-04,2024-11 · check-in free text available
-
2021-01-07
Survey response — day 14, dose 1MedDRA: Conjunctivitis, Rash — Feeling: GoodFree text: Developed conjunctivitis on Monday along with a rah to my inner legs and lower back. The conjunctivitis relived without intervention about 36 hours later. Rash iS still present.MedDRA releases: 2021-09,2023-04,2024-11 · check-in free text available
-
2021-01-12
Dose 2 — Pfizer-BioNTech
-
2021-01-14
Health check-in — days 1–6 daily, dose 2Feeling: Fair · Site: Pain · Fever · Headache, Muscle or body aches, Fatigue or tiredness, Nausea · Be unable to do your normal daily activitiesAdult check-in
-
2021-01-14
Report sent to call center — days 1–6 daily, dose 2Be unable to do your normal daily activities1 call case(s)
-
2021-01-16
Survey response — days 1–6 daily, dose 2MedDRA: Axillary pain — Feeling: GoodFree text: Ancillary pain on injection armMedDRA releases: 2021-09,2023-04,2024-11 · check-in free text available
- 2021-01-17
- 2021-01-18
- 2021-01-19
- 2021-01-26
- 2021-02-09
- 2021-04-13
-
2021-11-15
Dose 3 — Pfizer-BioNTech
- 2022-01-12
-
2023-04-21
Dose 4 — Moderna
-
2023-04-22
Survey response — days 1–6 daily, dose 4MedDRA: Lymphadenopathy — Feeling: Fair · Site: Pain · Fatigue or tiredness · Be unable to do your normal daily activitiesMedDRA releases: 2024-11
- 2023-04-23
-
2023-04-24
Survey response — days 1–6 daily, dose 4MedDRA: Lymphadenopathy — Feeling: GoodMedDRA releases: 2024-11
-
2023-04-25
Survey response — days 1–6 daily, dose 4MedDRA: Lymphadenopathy — Feeling: GoodMedDRA releases: 2024-11
-
2023-04-27
Survey response — days 1–6 daily, dose 4MedDRA: Lymphadenopathy — Feeling: GoodMedDRA releases: 2024-11
- 2023-05-05
Vaccinations
| Dose | Date | Manufacturer | Co-administered |
|---|---|---|---|
| 1 | 2020-12-22 | Pfizer-BioNTech | |
| 2 | 2021-01-12 | Pfizer-BioNTech | |
| 3 | 2021-11-15 | Pfizer-BioNTech | No |
| 4 | 2023-04-21 | Moderna | No |
Call center
| Reported | Outcome | VAERS-related outcome |
|---|---|---|
| 2021-01-14 | priority 2/3 |
Free text
Release 1 — day 7, dose 1
Systemic reaction (other): Pain under my left armpit but no palpable lymph node
Release 1 — day 14, dose 1
Symptoms: Developed conjunctivitis on Monday along with a rah to my inner legs and lower back. The conjunctivitis relived without intervention about 36 hours later. Rash iS still present.
Release 2 — days 1–6 daily, dose 2
Systemic reaction (other): Ancillary pain on injection arm
Each entry is dated by the survey it was written in (the CDC re-sent the releases with survey dates in 2025); click a date to see that survey response. The CDC cut some text off at about 250 characters: symptoms in every release, and the other two fields in releases 9-12. Those entries are marked "cut off by CDC".
MedDRA terms by release
| Field | Preferred term | 2021-09 | 2023-04 | 2024-11 |
|---|---|---|---|---|
| SD | Conjunctivitis | ✓ | ✓ | ✓ |
| SD | Rash | ✓ | ✓ | ✓ |
| SRO | Axillary pain | ✓ | ✓ | ✓ |
| SRO | Lymphadenopathy | · | · | ✓ |
✓ active code · ○ coded but marked inactive · blank = not in that release